On November 19, 2018, Dong Fan, the Chairman of Jafron Biomedical Co., Ltd., held a open ceremony with all managers at the headquarters, indicating that Jafron is on the new journey of collectivization development.
Jafron Biomedical Co., Ltd. (hereinafter referred to as “Jafron”) has multiple subsidiary companies, including Beijing Jafron Medical Equipment Co., Ltd., Tianjin Standard Biological Preparation Co., Ltd., Hubei Jafron Biomedical Co., Ltd., Hubei Jianshu Medical Materials Co., Ltd., Tianjin Jafron Biomedical Co., Ltd., Jafron Biomedical (Hong Kong) Co., Ltd. and Aiduoduo Health Management (Hengqin, Guangdong) Co., Ltd.. Its branch companies include Tianjin Research and Development Center of Jafron Biomedical Co., Ltd., Shenzhen Research and Development Center of Jafron Biomedical Co., Ltd. and Guangzhou Branch of Jafron Biomedical Co., Ltd..
Company profile:
Jafron was founded in 1989, specializing in the research and development, production and sales of biological materials and high-tech medical devices. It is the first A-share (GEM) listed company in China in the business of blood purification products (stock code: 300529). At present, it has 7 subsidiaries and 3 branches, topping the listed medical device companies in China in terms of market value. It has paid more than CNY 100 million in tax annually, and has been included into the list of 100 China Potential Enterprises in 2017 released by Forbes.
Jafron won the State Scientific and Technological Progress Award (Second Class) in 2009, was recognized as a National Torch Plan Key High-Tech Enterprise in 2011, and included in 2012 State Industry Revitalization and Technological Transformation Project, 2012 State Transformation Program of Major Scientific and Technological Achievements and 2014 National Science & Technology Pillar Program During the Twelfth Five-year Plan. The company specializes in R & D and production. Its sales network covers the whole country, and its product technology has reached the international advanced level. The world first-class blood purification scientific research and production base (Jafron science park) invested by the company was successfully completed and put into operation in 2015.
Jafron Biomedical Co., Ltd. (hereinafter referred to as “Jafron”) has multiple subsidiary companies, including Beijing Jafron Medical Equipment Co., Ltd., Tianjin Standard Biological Preparation Co., Ltd., Hubei Jafron Biomedical Co., Ltd., Hubei Jianshu Medical Materials Co., Ltd., Tianjin Jafron Biomedical Co., Ltd., Jafron Biomedical (Hong Kong) Co., Ltd. and Aiduoduo Health Management (Hengqin, Guangdong) Co., Ltd.. Its branch companies include Tianjin Research and Development Center of Jafron Biomedical Co., Ltd., Shenzhen Research and Development Center of Jafron Biomedical Co., Ltd. and Guangzhou Branch of Jafron Biomedical Co., Ltd..
Company profile:
Jafron was founded in 1989, specializing in the research and development, production and sales of biological materials and high-tech medical devices. It is the first A-share (GEM) listed company in China in the business of blood purification products (stock code: 300529). At present, it has 7 subsidiaries and 3 branches, topping the listed medical device companies in China in terms of market value. It has paid more than CNY 100 million in tax annually, and has been included into the list of 100 China Potential Enterprises in 2017 released by Forbes.
Jafron won the State Scientific and Technological Progress Award (Second Class) in 2009, was recognized as a National Torch Plan Key High-Tech Enterprise in 2011, and included in 2012 State Industry Revitalization and Technological Transformation Project, 2012 State Transformation Program of Major Scientific and Technological Achievements and 2014 National Science & Technology Pillar Program During the Twelfth Five-year Plan. The company specializes in R & D and production. Its sales network covers the whole country, and its product technology has reached the international advanced level. The world first-class blood purification scientific research and production base (Jafron science park) invested by the company was successfully completed and put into operation in 2015.